$AGIO
AGIOS PHARMACEUTICALS, INC.

2021 Q2 Form 10-Q Financial Statement

#000143922221000064 Filed on July 29, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $0.00 $37.35M
YoY Change -100.0% 42.43%
Cost Of Revenue $0.00 $675.0K
YoY Change -100.0% 122.77%
Gross Profit $0.00 $36.67M
YoY Change -100.0% 41.49%
Gross Profit Margin 98.19%
Selling, General & Admin $29.22M $35.95M
YoY Change -18.73% 10.99%
% of Gross Profit 98.03%
Research & Development $62.01M $54.09M
YoY Change 14.65% -49.64%
% of Gross Profit 147.49%
Depreciation & Amortization $2.329M $2.400M
YoY Change -2.96% 20.0%
% of Gross Profit 6.54%
Operating Expenses $62.01M $54.09M
YoY Change 14.65% -61.39%
Operating Profit -$91.22M -$83.26M
YoY Change 9.56% -26.87%
Interest Expense -$92.00K $1.770M
YoY Change -105.2% -55.64%
% of Operating Profit
Other Income/Expense, Net $6.524M $0.00
YoY Change
Pretax Income -$82.79M -$81.50M
YoY Change 1.59% -25.83%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$86.22M -$90.48M
YoY Change -4.71% -17.65%
Net Earnings / Revenue -242.26%
Basic Earnings Per Share -$1.41 -$1.31
Diluted Earnings Per Share -$1.41 -$1.31
COMMON SHARES
Basic Shares Outstanding 61.07M shares 68.96M shares
Diluted Shares Outstanding 61.07M shares 68.96M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.673B $790.1M
YoY Change 111.74% 59.49%
Cash & Equivalents $969.1M $295.9M
Short-Term Investments $703.9M $494.3M
Other Short-Term Assets $21.44M $27.00M
YoY Change -20.58% 41.36%
Inventory $11.23M
Prepaid Expenses
Receivables $13.70M
Other Receivables $8.131M $4.300M
Total Short-Term Assets $1.703B $846.4M
YoY Change 101.16% 58.58%
LONG-TERM ASSETS
Property, Plant & Equipment $27.06M $33.93M
YoY Change -20.25% 47.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $61.31M $4.300M
YoY Change 1325.88% -96.66%
Other Assets $2.900M $1.575M
YoY Change 84.13%
Total Long-Term Assets $172.0M $129.8M
YoY Change 32.56% -48.12%
TOTAL ASSETS
Total Short-Term Assets $1.703B $846.4M
Total Long-Term Assets $172.0M $129.8M
Total Assets $1.875B $976.1M
YoY Change 92.04% 24.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.654M $15.46M
YoY Change -50.49% 0.17%
Accrued Expenses $36.05M $41.91M
YoY Change -13.97% -14.85%
Deferred Revenue $0.00
YoY Change -100.0%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $839.0K $300.0K
YoY Change 179.67%
Total Short-Term Liabilities $60.65M $64.35M
YoY Change -5.76% -28.1%
LONG-TERM LIABILITIES
Long-Term Debt $167.0K $500.0K
YoY Change -66.6%
Other Long-Term Liabilities $91.97M $352.8M
YoY Change -73.93% 118.18%
Total Long-Term Liabilities $92.14M $353.3M
YoY Change -73.92% 118.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $60.65M $64.35M
Total Long-Term Liabilities $92.14M $353.3M
Total Liabilities $152.8M $417.7M
YoY Change -63.42% 66.28%
SHAREHOLDERS EQUITY
Retained Earnings -$55.37M -$1.647B
YoY Change -96.64% 25.95%
Common Stock $2.306B $2.204B
YoY Change 4.66% 19.78%
Preferred Stock
YoY Change
Treasury Stock (at cost) $529.0M
YoY Change
Treasury Stock Shares 10.49M shares
Shareholders Equity $1.722B $558.5M
YoY Change
Total Liabilities & Shareholders Equity $1.875B $976.1M
YoY Change 92.04% 24.53%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$86.22M -$90.48M
YoY Change -4.71% -17.65%
Depreciation, Depletion And Amortization $2.329M $2.400M
YoY Change -2.96% 20.0%
Cash From Operating Activities -$117.3M -$67.80M
YoY Change 73.07% -23.04%
INVESTING ACTIVITIES
Capital Expenditures -$261.0K -$4.200M
YoY Change -93.79% 223.08%
Acquisitions
YoY Change
Other Investing Activities -$297.9M $26.70M
YoY Change -1215.77% -59.36%
Cash From Investing Activities -$298.2M $22.50M
YoY Change -1425.21% -65.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -503.5M 252.1M
YoY Change -299.72% 6534.21%
NET CHANGE
Cash From Operating Activities -117.3M -67.80M
Cash From Investing Activities -298.2M 22.50M
Cash From Financing Activities -503.5M 252.1M
Net Change In Cash -919.0M 206.8M
YoY Change -544.4% -1139.2%
FREE CASH FLOW
Cash From Operating Activities -$117.3M -$67.80M
Capital Expenditures -$261.0K -$4.200M
Free Cash Flow -$117.1M -$63.60M
YoY Change 84.09% -26.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001439222
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36014
dei Entity Registrant Name
EntityRegistrantName
AGIOS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0662915
dei Entity Address Address Line1
EntityAddressAddressLine1
88 Sidney Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
649-8600
dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.001 per share
dei Trading Symbol
TradingSymbol
AGIO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58951469 shares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
969124000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
127436000 USD
CY2021Q2 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
703864000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
445493000 USD
CY2021Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
8131000 USD
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
21443000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15889000 USD
CY2021Q2 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 USD
CY2020Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
47859000 USD
CY2021Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
0 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
1702562000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
636677000 USD
CY2021Q2 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
61313000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
97608000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
79901000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
84661000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27056000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30815000 USD
CY2021Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
871000 USD
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
590000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2900000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2021Q2 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
0 USD
CY2020Q4 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
2601000 USD
CY2021Q2 us-gaap Assets
Assets
1874603000 USD
CY2020Q4 us-gaap Assets
Assets
852952000 USD
CY2021Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
167000 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
331000 USD
CY2020Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
261269000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
152787000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
453452000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7654000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17724000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36054000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30801000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8932000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7093000 USD
CY2021Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
839000 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
317000 USD
CY2021Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
7170000 USD
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
0 USD
CY2021Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 USD
CY2020Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
38459000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
60649000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
94394000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
91971000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
97458000 USD
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70404782 shares
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
1721816000 USD
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59910814 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69293920 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69293920 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
70000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
69000 USD
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2306304000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2242801000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-144000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
105000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55367000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1843475000 USD
CY2021Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
10493968 shares
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
0 shares
CY2021Q2 us-gaap Treasury Stock Value
TreasuryStockValue
529047000 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
399500000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1874603000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
852952000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62007000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54086000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
119674000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
109445000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29215000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29178000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
62765000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
60849000 USD
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
91222000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
83264000 USD
us-gaap Costs And Expenses
CostsAndExpenses
182439000 USD
us-gaap Costs And Expenses
CostsAndExpenses
170294000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-91222000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-83264000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-182439000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-170294000 USD
CY2021Q2 agio Contingent Gain On Disposition Of Business Recognized
ContingentGainOnDispositionOfBusinessRecognized
2000000 USD
CY2020Q2 agio Contingent Gain On Disposition Of Business Recognized
ContingentGainOnDispositionOfBusinessRecognized
0 USD
agio Contingent Gain On Disposition Of Business Recognized
ContingentGainOnDispositionOfBusinessRecognized
2000000 USD
agio Contingent Gain On Disposition Of Business Recognized
ContingentGainOnDispositionOfBusinessRecognized
0 USD
CY2021Q2 us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
-92000 USD
CY2020Q2 us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
1769000 USD
us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
248000 USD
us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
4705000 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6524000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6524000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-82790000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-81495000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-173667000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-165589000 USD
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-3427000 USD
CY2020Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-8983000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
1961775000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
34855000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-86217000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-90478000 USD
us-gaap Net Income Loss
NetIncomeLoss
1788108000 USD
us-gaap Net Income Loss
NetIncomeLoss
-130734000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.36
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.36
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.18
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.18
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.66
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.66
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.41
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.41
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61066977 shares
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.06
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.06
CY2020Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.13
CY2020Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.13
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
30.05
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
30.05
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.51
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.51
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
27.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
27.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.90
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61066977 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68958091 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68958091 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65281827 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65281827 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68784109 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68784109 shares
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-86217000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-90478000 USD
us-gaap Net Income Loss
NetIncomeLoss
1788108000 USD
us-gaap Net Income Loss
NetIncomeLoss
-130734000 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-141000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1562000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-249000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1434000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-86358000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-88916000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1787859000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-129300000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
399500000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7347000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14854000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-108000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
1874325000 USD
CY2021Q1 agio Stockholders Equity Disposition Of Business
StockholdersEquityDispositionOfBusiness
-712000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
2296630000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25673000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14885000 USD
CY2021Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
529047000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-141000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-86217000 USD
CY2021Q2 agio Stockholders Equity Disposition Of Business
StockholdersEquityDispositionOfBusiness
-33000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
1721816000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
640528000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5465000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15670000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-128000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-40256000 USD
CY2020Q1 agio Stockholders Equity Disposition Of Business
StockholdersEquityDispositionOfBusiness
-4020000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
625299000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1652000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17614000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1562000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-90478000 USD
CY2020Q2 agio Stockholders Equity Disposition Of Business
StockholdersEquityDispositionOfBusiness
-2816000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
558465000 USD
us-gaap Net Income Loss
NetIncomeLoss
1788108000 USD
us-gaap Net Income Loss
NetIncomeLoss
-130734000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
1961775000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
34855000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-173667000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-165589000 USD
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
4829000 USD
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
4887000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
29739000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
33284000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3422000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-473000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-12000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
agio Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
4760000 USD
agio Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
4435000 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
8131000 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8454000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1295000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5561000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2562000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2547000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-8265000 USD
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3631000 USD
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4149000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-159229000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-136191000 USD
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-78814000 USD
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-36964000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-238043000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-173155000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
498896000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
189601000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
273149000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
328883000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1261000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8340000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-227008000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
130942000 USD
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
1802936000 USD
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-348000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1575928000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
130594000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
170000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
166000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
529047000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
33020000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7117000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-496197000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6951000 USD
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
0 USD
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
250537000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-496197000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
257488000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
841688000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
214927000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127436000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80931000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
969124000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
295858000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
56000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3621000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
511000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 USD
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of the oncology business in order to conform to the current period presentation.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and any variant strains of the virus and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div>
CY2021Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
1700000000 USD
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-3427000 USD
CY2020Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-8983000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
1961775000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
34855000 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
CY2021Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
CY2020Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
CY2021Q2 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
765321000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
29000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
173000 USD
CY2021Q2 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
765177000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
542996000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
321000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
216000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
543101000 USD
CY2021Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
113 security
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
87 security
CY2020Q4 us-gaap Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
0 USD
CY2021Q2 us-gaap Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
0 USD
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
559300000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
299000000.0 USD
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 security
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 security
CY2021Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P7Y
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3800000 USD
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3800000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
7600000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
7600000 USD
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
3600000 USD
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
3500000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
7200000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
7400000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
6039000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
16773000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
18126000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
18660000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
19507000 USD
CY2021Q2 agio Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
44385000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
123490000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
22587000 USD
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
100903000 USD
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y2M12D
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10559000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
20345000 USD
CY2021Q2 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
7627000 USD
CY2020Q4 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5444000 USD
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3075000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2897000 USD
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
14793000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2115000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36054000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30801000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6143046 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
58.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
999488 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
56.17
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
677154 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
45.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1213538 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
61.89
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5251842 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
58.87
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3412161 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
61.00
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5251842 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
58.87
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14885000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17614000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29739000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33284000 USD
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14885000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17614000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29739000 USD
CY2021Q2 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33284000 USD
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6466277 shares
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8132598 shares
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
12900000 USD
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0 USD
CY2020Q2 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
6200000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD

Files In Submission

Name View Source Status
0001439222-21-000064-index-headers.html Edgar Link pending
0001439222-21-000064-index.html Edgar Link pending
0001439222-21-000064.txt Edgar Link pending
0001439222-21-000064-xbrl.zip Edgar Link pending
agio-20210630.htm Edgar Link pending
agio-20210630.xsd Edgar Link pending
agio-20210630_cal.xml Edgar Link unprocessable
agio-20210630_def.xml Edgar Link unprocessable
agio-20210630_htm.xml Edgar Link completed
agio-20210630_lab.xml Edgar Link unprocessable
agio-20210630_pre.xml Edgar Link unprocessable
exhibit31-1x06x30x21.htm Edgar Link pending
exhibit31-2x06x30x21.htm Edgar Link pending
exhibit32-1x06x30x21.htm Edgar Link pending
exhibit32-2x06x30x21.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending